Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ASCO Annual Meeting 2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

2024 ASCO Annual Meeting

Keep up to date with all the top stories and latest evidence with our hub page, including official congress videos and expert takeaways.
ADVANCED SEARCH
Log in
Top
Discover Oncology
Published in: Discover Oncology 1/2023

Open Access 01-12-2023 | Cervical Cancer | Research

Investigating the potential mechanism of quercetin against cervical cancer

Authors: Man Chu, Huihui Ji, Kehan Li, Hejing Liu, Mengjia Peng, Zhiwei Wang, Xueqiong Zhu

Published in: Discover Oncology | Issue 1/2023

Login to get access

Abstract

Background

Cervical cancer is emerging as a potential target of increased susceptibility to coronavirus disease-2019 (COVID-19), leading to compromised survival rates. Despite this critical link, efficacious anti-cervical cancer/COVID-19 interventions remain limited. Quercetin, known for its efficacy against both cancer and viral infections, holds promise as a therapeutic agent. This study aims to elucidate quercetin’s anti-cervical cancer/COVID-19 mechanisms and potential targets.

Methods

We initiated our investigation with differential gene expression analysis using cervical cancer transcriptome data from The Cancer Genome Atlas (TCGA) and The Genotype-Tissue Expression (GTEx), focusing on intersections with COVID-19-related genes. Network pharmacology was employed to identify the shared targets between cervical cancer/COVID-19 DEGs and quercetin’s targets. Subsequently, Cox proportional hazards analyses were employed to establish a risk score based on these genes. Molecular docking techniques were applied to predict quercetin’s therapeutic targets and mechanisms for mitigating cervical cancer and COVID-19.

Results

Our findings unveiled 45 potential quercetin targets with anti-cervical cancer/COVID-19 actions. Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) analyses highlighted significant enrichment in immune pathways and COVID-19-related pathways. A refined risk score model, comprising PLA2G7, TNF, TYK2, F2, and NRP1, effectively stratified cervical cancer patients into distinct risk groups. Importantly, molecular docking analyses illuminated quercetin’s remarkable binding affinity to the primary protease of the coronavirus.

Conclusions

In summation, our study suggests that quercetin holds promise as a potential therapeutic agent for mitigating coronavirus function, specifically through its interaction with the primary protease. This research offers novel insights into exploring COVID-19 susceptibility and enhancing survival in cervical cancer patients.
Literature
1.
Lotfinejad P, Asadzadeh Z, Najjary S, Somi MH, Hajiasgharzadeh K, Mokhtarzadeh A, et al. COVID-19 infection: concise review based on the immunological perspective. Immunol Invest. 2022;51:246–65.PubMed
2.
Chen Q, Zhang J, Wang P, Zhang Z. The mechanisms of immune response and evasion by the main SARS-CoV-2 variants. iScience. 2022;25:105044.PubMedPubMedCentral
3.
Hu B, Guo H, Zhou P, Shi ZL. Characteristics of SARS-CoV-2 and COVID-19. Nat Rev Microbiol. 2021;19:141–54.PubMed
4.
Cao B, Wang Y, Wen D, Liu W, Wang J, Fan G, et al. A trial of lopinavir-ritonavir in adults hospitalized with severe Covid-19. N Engl J Med. 2020;382:1787–99.PubMed
5.
Han HJ, Nwagwu C, Anyim O, Ekweremadu C, Kim S. COVID-19 and cancer: from basic mechanisms to vaccine development using nanotechnology. Int Immunopharmacol. 2021;90:107247.PubMed
6.
Arbyn M, Weiderpass E, Bruni L, de Sanjosé S, Saraiya M, Ferlay J, et al. Estimates of incidence and mortality of cervical cancer in 2018: a worldwide analysis. Lancet Glob Health. 2020;8:e191–e203.PubMed
7.
Cohen PA, Jhingran A, Oaknin A, Denny L. Cervical cancer. Lancet. 2019;393:169–82.PubMed
8.
Siegel RL, Miller KD, Fuchs HE, Jemal A. Cancer statistics. CA Cancer J Clin. 2021;71:7–33.PubMed
9.
Perkins RB, Wentzensen N, Guido RS, Schiffman M. Cervical cancer screening: a review. JAMA. 2023;330:547–58.PubMed
10.
Kamboj M, Sepkowitz KA. Nosocomial infections in patients with cancer. Lancet Oncol. 2009;10:589–97.PubMed
11.
Sica A, Massarotti M. Myeloid suppressor cells in cancer and autoimmunity. J Autoimmun. 2017;85:117–25.PubMed
12.
Wu Z, McGoogan JM. Characteristics of and important Lessons from the Coronavirus Disease 2019 (COVID-19) outbreak in China: summary of a report of 72 314 cases from the Chinese Center for Disease Control and Prevention. JAMA. 2020;323:1239–42.PubMed
13.
Fraga CG, Croft KD, Kennedy DO, Tomás-Barberán FA. The effects of polyphenols and other bioactives on human health. Food Funct. 2019;10:514–28.PubMed
14.
Rauf A, Imran M, Khan IA, Ur-Rehman M, Gilani SA, Mehmood Z, et al. Anticancer potential of quercetin: a comprehensive review. Phytother Res. 2018;32:2109–30.PubMed
15.
Xu D, Hu MJ, Wang YQ, Cui YL. Antioxidant activities of quercetin and its complexes for medicinal application. Molecules. 2019;24:1123.PubMedPubMedCentral
16.
Reyes-Farias M, Carrasco-Pozo C. The anti-cancer effect of quercetin: molecular implications in cancer metabolism. Int J Mol Sci. 2019;20:3177.PubMedPubMedCentral
17.
Tang SM, Deng XT, Zhou J, Li QP, Ge XX, Miao L. Pharmacological basis and new insights of quercetin action in respect to its anti-cancer effects. Biomed Pharmacother. 2020;121:109604.PubMed
18.
Colunga Biancatelli RML, Berrill M, Catravas JD, Marik PE, Quercetin, Vitamin C. An experimental, synergistic therapy for the prevention and treatment of SARS-CoV-2 related disease (COVID-19). Front Immunol. 2020;11:1451.PubMedPubMedCentral
19.
Song X, Zhang Y, Dai E, Wang L, Du H. Prediction of triptolide targets in rheumatoid arthritis using network pharmacology and molecular docking. Int Immunopharmacol. 2020;80:106179.PubMed
20.
Aihaiti Y, Song Cai Y, Tuerhong X, Ni Yang Y, Ma Y, Shi Zheng H, et al. Therapeutic effects of naringin in rheumatoid arthritis: network pharmacology and experimental validation. Front Pharmacol. 2021;12:672054.PubMedPubMedCentral
21.
Gussow AB, Auslander N, Faure G, Wolf YI, Zhang F, Koonin EV. Genomic determinants of pathogenicity in SARS-CoV-2 and other human coronaviruses. Proc Natl Acad Sci U S A. 2020;117:15193–9.PubMedPubMedCentral
22.
Carithers LJ, Ardlie K, Barcus M, Branton PA, Britton A, Buia SA, et al. A novel approach to high-quality postmortem tissue procurement: the GTEx project. Biopreserv Biobank. 2015;13:311–9.PubMedPubMedCentral
23.
Gu Z, Eils R, Schlesner M. Complex heatmaps reveal patterns and correlations in multidimensional genomic data. Bioinformatics. 2016;32:2847–9.PubMed
24.
Love MI, Huber W, Anders S. Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2. Genome Biol. 2014;15:550.PubMedPubMedCentral
25.
Davis AP, Grondin CJ, Johnson RJ, Sciaky D, Wiegers J, Wiegers TC, et al. Comparative toxicogenomics database (CTD): update 2021. Nucleic Acids Res. 2021;49:D1138–d1143.PubMed
26.
Wishart DS, Feunang YD, Guo AC, Lo EJ, Marcu A, Grant JR, et al. DrugBank 5.0: a major update to the DrugBank database for 2018. Nucleic Acids Res. 2018;46:D1074–d1082.PubMed
27.
Gfeller D, Grosdidier A, Wirth M, Daina A, Michielin O, Zoete V. SwissTargetPrediction: a web server for target prediction of bioactive small molecules. Nucleic Acids Res. 2014;42:W32–38.PubMedPubMedCentral
28.
Yao ZJ, Dong J, Che YJ, Zhu MF, Wen M, Wang NN, et al. TargetNet: a web service for predicting potential drug-target interaction profiling via multi-target SAR models. J Comput Aided Mol Des. 2016;30:413–24.PubMed
29.
30.
Ashburner M, Ball CA, Blake JA, Botstein D, Butler H, Cherry JM, et al. Gene ontology: tool for the unification of biology. The Gene Ontology Consortium. Nat Genet. 2000;25:25–9.PubMedPubMedCentral
31.
Raudvere U, Kolberg L, Kuzmin I, Arak T, Adler P, Peterson H, et al. G:profiler: a web server for functional enrichment analysis and conversions of gene lists (2019 update). Nucleic Acids Res. 2019;47:W191–w198.PubMedCentral
32.
Szklarczyk D, Gable AL, Nastou KC, Lyon D, Kirsch R, Pyysalo S, et al. The STRING database in 2021: customizable protein-protein networks, and functional characterization of user-uploaded gene/measurement sets. Nucleic Acids Res. 2021;49:D605–d612.PubMed
33.
Shannon P, Markiel A, Ozier O, Baliga NS, Wang JT, Ramage D, et al. Cytoscape: a software environment for integrated models of biomolecular interaction networks. Genome Res. 2003;13:2498–504.PubMedPubMedCentral
34.
Li B, Severson E, Pignon JC, Zhao H, Li T, Novak J, et al. Comprehensive analyses of tumor immunity: implications for cancer immunotherapy. Genome Biol. 2016;17:174.PubMedPubMedCentral
35.
Zeng D, Ye Z, Wu J, Zhou R, Fan X, Wang G, et al. Macrophage correlates with immunophenotype and predicts anti-PD-L1 response of urothelial cancer. Theranostics. 2020;10:7002–14.PubMedPubMedCentral
36.
Trott O, Olson AJ. AutoDock Vina: improving the speed and accuracy of docking with a new scoring function, efficient optimization, and multithreading. J Comput Chem. 2010;31:455–61.PubMedCentral
37.
Berman HM, Westbrook J, Feng Z, Gilliland G, Bhat TN, Weissig H, et al. The protein data bank. Nucleic Acids Res. 2000;28:235–42.PubMedPubMedCentral
38.
Seeliger D, de Groot BL. Ligand docking and binding site analysis with PyMOL and Autodock/Vina. J Comput Aided Mol Des. 2010;24:417–22.PubMedPubMedCentral
39.
Li X, Liang W, Yu C, Meng Q, Zhang W, Wu X, et al. Potential therapeutic strategies for quercetin targeting critical pathological mechanisms associated with colon adenocarcinoma and COVID-19. Front Pharmacol. 2022;13:988153.PubMedPubMedCentral
40.
Ji H, Li K, Xu W, Li R, Xie S, Zhu X. Prediction of the mechanisms by which quercetin enhances cisplatin action in cervical cancer: a network pharmacology study and experimental validation. Front Oncol. 2021;11:780387.PubMed
41.
Lin M, Pan C, Xu W, Li J, Zhu X. Leonurine promotes cisplatin sensitivity in human cervical Cancer cells through increasing apoptosis and inhibiting drug-resistant proteins. Drug Des Devel Ther. 2020;14:1885–95.PubMedPubMedCentral
42.
Salomon BL, Leclerc M, Tosello J, Ronin E, Piaggio E, Cohen JL. Tumor necrosis factor α and regulatory T cells in oncoimmunology. Front Immunol. 2018;9:444.PubMedPubMedCentral
43.
Vredevoogd DW, Kuilman T, Ligtenberg MA, Boshuizen J, Stecker KE, de Bruijn B, et al. Augmenting immunotherapy impact by lowering Tumor TNF cytotoxicity threshold. Cell. 2019;178:585–599e515.PubMed
44.
Balkwill F. Tumour necrosis factor and cancer. Nat Rev Cancer. 2009;9:361–71.PubMed
45.
Sha J, Du J, Yang J, Hu X, Li L. Changes of serum levels of tumor necrosis factor (TNF-α) and soluble interleukin-2 receptor (SIL 2R) in patients with cervical cancer and their clinical significance. Am J Transl Res. 2021;13:6599–604.PubMedPubMedCentral
46.
Babapour N, Mehramiz M, Rastgar Moghadam A, Behboodi N, Yousefi Z, Maftouh M, et al. Association of TNF-308 G > A polymorphism located in tumor necrosis factor a with the risk of developing cervical cancer and results of pap smear. J Cell Biochem. 2019;120:5444–8.PubMed
47.
Li L, Liu J, Liu C, Lu X. The correlation between TNF-α-308 gene polymorphism and susceptibility to cervical cancer. Oncol Lett. 2018;15:7163–7.PubMedPubMedCentral
48.
Du GH, Wang JK, Richards JR, Wang JJ. Genetic polymorphisms in tumor necrosis factor alpha and interleukin-10 are associated with an increased risk of cervical cancer. Int Immunopharmacol. 2019;66:154–61.PubMed
49.
Martin-Fernandez L, Ziyatdinov A, Carrasco M, Millon JA, Martinez-Perez A, Vilalta N, et al. Genetic determinants of Thrombin Generation and their relation to venous thrombosis: results from the GAIT-2 Project. PLoS ONE. 2016;11:e0146922.PubMedPubMedCentral
50.
McFadyen JD, Stevens H, Peter K. The emerging threat of (Micro)thrombosis in COVID-19 and its therapeutic implications. Circ Res. 2020;127:571–87.PubMedPubMedCentral
51.
Campello E, Bulato C, Spiezia L, Boscolo A, Poletto F, Cola M, et al. Thrombin generation in patients with COVID-19 with and without thromboprophylaxis. Clin Chem Lab Med. 2021;59:1323–30.PubMed
52.
Dong Y, Ma WM, Shi ZD, Zhang ZG, Zhou JH, Li Y, et al. Role of NRP1 in bladder cancer pathogenesis and progression. Front Oncol. 2021;11:685980.PubMedPubMedCentral
53.
Chen XJ, Wu S, Yan RM, Fan LS, Yu L, Zhang YM, et al. The role of the hypoxia-Nrp-1 axis in the activation of M2-like tumor-associated macrophages in the tumor microenvironment of cervical cancer. Mol Carcinog. 2019;58:388–97.PubMed
54.
Yang L, Liu L, Zhu YH, Wang BB, Chen YN, Zhang F, et al. Neuropilin-1 is associated with the prognosis of cervical cancer in Henan Chinese population. Onco Targets Ther. 2019;12:2911–20.PubMedPubMedCentral
55.
Dai J, Pan Y, Chen Y, Yao S. A panel of seven immune-related genes can serve as a good predictive biomarker for cervical squamous cell carcinoma. Front Genet. 2022;13:1024508.PubMedPubMedCentral
56.
Battaglia A, Buzzonetti A, Monego G, Peri L, Ferrandina G, Fanfani F, et al. Neuropilin-1 expression identifies a subset of regulatory T cells in human lymph nodes that is modulated by preoperative chemoradiation therapy in cervical cancer. Immunology. 2008;123:129–38.PubMedPubMedCentral
57.
Yang S, Cheng H, Huang Z, Wang X, Wan Y, Cai J, et al. Circulating soluble neuropilin-1 in patients with early cervical cancer and cervical intraepithelial neoplasia can be used as a valuable diagnostic biomarke. Dis Markers. 2015;2015:506428.PubMedPubMedCentral
58.
Yang B, Chen J, Teng Y. TNPO1-mediated nuclear import of fubp1 contributes to tumor immune evasion by increasing NRP1 expression in cervical cancer. J Immunol Res. 2021;2021:9994004.PubMedPubMedCentral
59.
Akbari M, Akhavan-Bahabadi M, Shafigh N, Taheriazam A, Hussen BM, Sayad A, et al. Expression analysis of IFNAR1 and TYK2 transcripts in COVID-19 patients. Cytokine. 2022;153:155849.PubMedPubMedCentral
60.
Pairo-Castineira E, Clohisey S, Klaric L, Bretherick AD, Rawlik K, Pasko D, et al. Genetic mechanisms of critical illness in COVID-19. Nature. 2021;591:92–8.PubMed
61.
Zheng W, Lin Q, Issah MA, Liao Z, Shen J. Identification of PLA2G7 as a novel biomarker of diffuse large B cell lymphoma. BMC Cancer. 2021;21:927.PubMedPubMedCentral
62.
Lehtinen L, Vainio P, Wikman H, Huhtala H, Mueller V, Kallioniemi A, et al. PLA2G7 associates with hormone receptor negativity in clinical breast cancer samples and regulates epithelial-mesenchymal transition in cultured breast cancer cells. J Pathol Clin Res. 2017;3:123–38.PubMedPubMedCentral
63.
Vainio P, Lehtinen L, Mirtti T, Hilvo M, Seppänen-Laakso T, Virtanen J, et al. Phospholipase PLA2G7, associated with aggressive prostate cancer, promotes prostate cancer cell migration and invasion and is inhibited by statins. Oncotarget. 2011;2:1176–90.PubMedPubMedCentral
64.
Vainio P, Gupta S, Ketola K, Mirtti T, Mpindi JP, Kohonen P, et al. Arachidonic acid pathway members PLA2G7, HPGD, EPHX2, and CYP4F8 identified as putative novel therapeutic targets in prostate cancer. Am J Pathol. 2011;178:525–36.PubMedPubMedCentral
65.
Morigny P, Kaltenecker D, Zuber J, Machado J, Mehr L, Tsokanos FF, et al. Association of circulating PLA2G7 levels with cancer cachexia and assessment of darapladib as a therapy. J Cachexia Sarcopenia Muscle. 2021;12:1333–51.PubMedPubMedCentral
66.
Xu C, Reichert EC, Nakano T, Lohse M, Gardner AA, Revelo MP, et al. Deficiency of phospholipase A2 group 7 decreases intestinal polyposis and colon tumorigenesis in apc(Min/+) mice. Cancer Res. 2013;73:2806–16.PubMedPubMedCentral
67.
Liao Y, Badmann S, Kraus F, Topalov NE, Mayr D, Kolben T, et al. PLA2G7/PAF-AH as potential negative regulator of the Wnt signaling pathway mediates protective effects in BRCA1 mutant breast cancer. Int J Mol Sci. 2023;24:882.PubMedPubMedCentral
68.
Liao Y, Badmann S, Kaltofen T, Mayr D, Schmoeckel E, Deuster E, et al. Platelet-activating factor acetylhydrolase expression in BRCA1 mutant ovarian cancer as a protective factor and potential negative regulator of the Wnt signaling pathway. Biomedicines. 2021;9:706.PubMedPubMedCentral
69.
Zalpoor H, Bakhtiyari M, Liaghat M, Nabi-Afjadi M, Ganjalikhani-Hakemi M. Quercetin potential effects against SARS-CoV-2 infection and COVID-19-associated cancer progression by inhibiting mTOR and hypoxia-inducible factor-1alpha (HIF-1alpha). Phytother Res. 2022;36:2679–82.PubMedPubMedCentral
70.
Kedhari Sundaram M, Raina R, Afroze N, Bajbouj K, Hamad M, Haque S, et al. Quercetin modulates signaling pathways and induces apoptosis in cervical cancer cells. Biosci Rep. 2019;39:BSR20190720.PubMedPubMedCentral
Metadata
Title
Investigating the potential mechanism of quercetin against cervical cancer
Authors
Man Chu
Huihui Ji
Kehan Li
Hejing Liu
Mengjia Peng
Zhiwei Wang
Xueqiong Zhu
Publication date
01-12-2023
Publisher
Springer US
Published in
Discover Oncology / Issue 1/2023
Print ISSN: 1868-8497
Electronic ISSN: 2730-6011
DOI
https://doi.org/10.1007/s12672-023-00788-y

Other articles of this Issue 1/2023

Discover Oncology 1/2023 Go to the issue

Research

SDH mutations, as potential predictor of chemotherapy prognosis in small cell lung cancer patients

Research

Virus-like particle-based delivery of Cas9/guide RNA ribonucleoprotein efficiently edits the brachyury gene and inhibits chordoma growth in vivo

Research

A MRI-based radiomics model for predicting the response to anlotinb combined with temozolomide in recurrent malignant glioma patients

Research

Glutamine is a substrate for glycosylation and CA19-9 biosynthesis through hexosamine biosynthetic pathway in pancreatic cancer

Research

β-Arrestin2 promotes docetaxel resistance of castration-resistant prostate cancer via promoting hnRNP A1-mediated PKM2 alternative splicing

Research

MOB kinase activator 1A acts as an oncogene by targeting PI3K/AKT/mTOR in ovarian cancer
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine
Image Credits